Vasodilators for use in the treatment of a retinal ischemic disorder
AssigneesUniversity of Copenhagen, Rigshospitalet
InventorsKristian Agmund Haanes, Vadim Fedulov, Lars Edvinsson, Karin Warfvinge
Life of this patent
Estimating the term…
Abstract
The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.
Claims13
A vasodilator for use in the treatment of a retinal ischemic disorder in a mammal, wherein the vasodilator acts via the calcitonin receptor-like receptor (CRLR/RAMP-1) and wherein the vasodilator comprise a peptide motif in the C-terminal end having at least 50% identity to SEQ ID NO:
- 9.
A CRLR/RAMP 1 agonist for use in the treatment of a retinal ischemic disorder in a mammal, wherein said CRLR/RAMP 1 agonist is a compound which
- (1) has a KD of less than 1 μM, and
- (2) causes cAMP accumulation in a cell line that expresses the CRLR/RAMP1 receptor with an EC50 of less than 10 μM.
Dependencies are inferred from the claim text.